Paroxysmal Cold Hemoglobinuria
Paroxysmal cold hemoglobinuria is a rare cause of autoimmune hemolytic anemia predominantly seen as an acute form in young children after viral illnesses and in a chronic form in some…
Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia
Cold antibody types account for about 25% of autoimmune hemolytic anemias. Primary chronic cold agglutinin disease (CAD) is characterized by a clonal lymphoproliferative disorder. Secondary cold agglutinin syndrome (CAS) complicates…
Hemolysis from ABO Incompatibility
ABO incompatibility of red blood cells leads to brisk complement-mediated lysis, particularly in the setting of red cell transfusion. The ABO blood group is the most clinically significant blood group…
Warm Autoimmune Hemolytic Anemia
Warm autoimmune hemolytic anemia (AIHA) is defined as the destruction of circulating red blood cells (RBCs) in the setting of anti-RBC autoantibodies that optimally react at 37°C. The pathophysiology of…
Complement
The complement system is an essential component of the immune system. It is a highly integrative system and has a number of functions, including host defense, removal of injured cells…
Complement in Health and Disease
Robert A. Brodsky, MD, Editor Related posts: Complement Paroxysmal Nocturnal Hemoglobinuria Congenital CD59 Deficiency Warm Autoimmune Hemolytic Anemia Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia Current and Future Pharmacologic Complement Inhibitors
Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma
Since the US Food and Drug Administration’s approval of gemcitabine in 1996, numerous randomized trials have investigated treatment programs to further improve the quality of life and survival of patients…
Novel Therapeutics for Pancreatic Adenocarcinoma
The last decade has seen significant developments in the use of combination systemic therapy for advanced pancreatic ductal adenocarcinoma (PDAC), with median survival approaching 1 year for select patients treated with…
Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma
Borderline resectable pancreatic cancer represents a subcategory of advanced cancer that is typically defined by limited involvement of the major mesenteric vasculature. Such involvement is associated with a high likelihood…
Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma
This article focuses on the management of locally advanced pancreatic cancer, which should be treated as a distinct entity separate from metastatic disease and borderline resectable disease. Although the role,…
